Advertisement
UK markets closed
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • CRUDE OIL

    85.34
    -0.07 (-0.08%)
     
  • GOLD FUTURES

    2,401.30
    +18.30 (+0.77%)
     
  • DOW

    37,798.97
    +63.86 (+0.17%)
     
  • Bitcoin GBP

    50,639.17
    -243.43 (-0.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,865.25
    -19.77 (-0.12%)
     
  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio

Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.